GLP-1s vs. Naltrexone, Disulfiram, and Acamprosate: How the New Option Compares
The Current Toolkit: Three Medications in 70 Years
The FDA has approved exactly three medications for alcohol use disorder. Disulfiram (Antabuse) was approved in 1951. Naltrexone (ReVia, Vivitrol) was approved in 1994. Acamprosate (Campral) was approved in 2004. Despite decades of research, no new medication has been added since — a span that underscores just how difficult AUD treatment development has been.
Each medication works through a different mechanism, has distinct strengths and limitations, and works better for some patients than others. Understanding these differences matters because semaglutide, if eventually approved for AUD, would offer a fundamentally different approach from all three.
Head-to-Head Comparison
| Factor | Disulfiram | Naltrexone | Acamprosate | Semaglutide (investigational) |
|---|---|---|---|---|
| Brand names | Antabuse | ReVia (oral), Vivitrol (injection) | Campral | Ozempic, Wegovy (not AUD-approved) |
| FDA approved for AUD | 1951 | 1994 | 2004 | Not yet (Phase 3 trials underway) |
| How it works | Aversion: blocks alcohol metabolism, causing severe nausea if you drink | Opioid receptor blockade: reduces the pleasurable "buzz" from alcohol | GABA/glutamate stabilization: reduces post-acute withdrawal distress | Reward pathway modulation: dampens craving drive via dopamine, GABA, and glutamate in the VTA/NAc |
| Goal | Complete abstinence (drinking on it makes you sick) | Reduced heavy drinking or abstinence | Maintaining abstinence after detox | Reduced craving and consumption |
| Dosing | Daily pill | Daily pill or monthly injection | Three times daily pill | Weekly injection |
| Works across substances? | No (alcohol only) | Partially (blocks opioid effects too) | No (alcohol only) | Potentially yes — data shows effects across all major substances |
| Common side effects | Drowsiness, metallic taste, hepatotoxicity risk | Nausea, headache, fatigue | Diarrhea, nausea | Nausea, constipation, appetite reduction |
| Key limitation | Requires daily compliance; ineffective if patient drinks anyway | Cannot use with opioid medications; requires opioid-free period | Three-times-daily dosing; only works for maintaining abstinence, not achieving it | Not yet approved; high cost; requires injection; strongest data in patients who also have obesity |
The Mechanism That Makes Semaglutide Different
Disulfiram: Punishment
Disulfiram doesn't reduce craving at all. It works through deterrence — if you drink while taking it, you'll feel extremely sick. This requires complete adherence (taking the pill every day) and a patient who is motivated enough to maintain that adherence even when craving is high. Supervised administration improves outcomes, but in practice, many patients simply stop taking it when they want to drink.
Naltrexone: Blocking the Buzz
Naltrexone works by making alcohol less rewarding — the "buzz" is diminished. Over time, this can lead to reduced drinking through a process called pharmacological extinction. It's particularly effective in people who drink for the euphoric effects rather than to relieve anxiety. The monthly injectable form (Vivitrol) solves the daily compliance problem. However, naltrexone cannot be used by people taking opioid medications or who have not completed opioid detox — a significant limitation given the overlap between AUD and opioid use.
Acamprosate: Stabilizing After Withdrawal
Acamprosate works best after a patient has already achieved abstinence. It helps maintain that abstinence by reducing the protracted withdrawal symptoms (anxiety, insomnia, dysphoria) that drive relapse. It does not reduce craving in the traditional sense and is not effective for initiating abstinence. The three-times-daily dosing schedule is also a practical barrier.
Semaglutide (Investigational): Quieting the Craving
Semaglutide's proposed mechanism is fundamentally different from the existing three medications. Rather than punishing drinking (disulfiram), blocking the buzz (naltrexone), or stabilizing withdrawal (acamprosate), it appears to address the craving itself — the motivational pull that drives the decision to drink in the first place. It works upstream of the other medications, at the level of incentive salience.
This mechanism has a potential advantage: it may work regardless of whether the patient is drinking to feel good (positive reinforcement) or to stop feeling bad (negative reinforcement). Both pathways converge on the dopamine reward circuitry that GLP-1 agonists modulate.
Could They Work Together?
One of the most intriguing possibilities is combination therapy. Because semaglutide works through a different mechanism than any of the existing AUD medications, it could potentially be used alongside them rather than replacing them. A patient might take naltrexone to block the acute rewarding effects of alcohol while taking semaglutide to reduce the underlying craving drive — addressing both the reward and the motivation simultaneously.
No clinical trials have tested these combinations, but the theoretical rationale is strong. In addiction medicine more broadly, combination therapy (such as buprenorphine + naloxone for OUD) often outperforms single-agent approaches.
What Semaglutide Can't Do (Yet)
Semaglutide is not FDA-approved for AUD. The Lancet trial published in May 2026, while positive, was a single-center study of 108 patients. Phase 3 trials — the large, multi-center studies required for regulatory approval — are underway but not yet complete. The timeline to potential FDA approval, if the trials succeed, is likely several years away.
The cost is also a significant consideration. GLP-1 medications for weight loss currently cost over $1,000 per month without insurance, and insurance coverage for AUD would require FDA approval and separate coverage decisions. For a condition that disproportionately affects lower-income populations, access is a critical concern.
The Practical Takeaway
If you or someone you know has AUD, effective medications exist right now. Naltrexone, disulfiram, and acamprosate are all available, generic, and covered by most insurance plans — but fewer than 10% of people with AUD are prescribed them. The biggest barrier to treatment isn't the lack of medication options; it's underutilization of the ones we already have.
The NIAAA Alcohol Treatment Navigator can help find evidence-based care options near you.
Sources
- Klausen MK, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity. The Lancet. 2026;407(10540):1687-1698.
- Modesto-Lowe V, Sgambato D. Semaglutide for alcohol use disorder. Prim Care Companion CNS Disord. 2025;27(6):25lr04040.
- NIAAA. Understanding Alcohol Use Disorder. National Institute on Alcohol Abuse and Alcoholism. 2024.
- Jonas DE, et al. Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings: A Systematic Review and Meta-analysis. JAMA. 2014;311(18):1889-1900.